174 related articles for article (PubMed ID: 24825115)
1. Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
Pho MT; Linas BP
Hepatology; 2014 Jul; 60(1):12-4. PubMed ID: 24825115
[No Abstract] [Full Text] [Related]
2. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
3. The good, the bad and the ugly of the new treatments for hepatitis C virus.
Silva-Vidal KV; Méndez-Sánchez N
Ann Hepatol; 2014; 13(5):574-5. PubMed ID: 25152995
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
5. The price of good health.
Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
[TBL] [Abstract][Full Text] [Related]
6. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Hill A; Khoo S; Fortunak J; Simmons B; Ford N
Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
[TBL] [Abstract][Full Text] [Related]
7. Medicine. Hepatitis C can be cured globally, but at what cost?
Hill A; Cooke G
Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
[No Abstract] [Full Text] [Related]
8. WHO issues guidelines on HCV amid drug cost controversy.
Slomski A
JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
10. Special report: cost-effectiveness studies of new hepatitis C treatments.
Mark DH;
Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
12. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
Campos-Varela I; Straley S; Agudelo EZ; Carlson L; Terrault NA
Liver Transpl; 2015 Feb; 21(2):272-4. PubMed ID: 25332190
[No Abstract] [Full Text] [Related]
15. FDA approvals usher in the post-interferon era in HCV.
Sheridan C
Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
[No Abstract] [Full Text] [Related]
16. Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
Abdel-Razek W; Waked I
Liver Int; 2015 Jan; 35 Suppl 1():27-34. PubMed ID: 25529085
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis C virus infection in the near future.
Cheinquer H
Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
[No Abstract] [Full Text] [Related]
18. HCV F1/F2 patients: treat now or continue to wait.
Shiffman ML; Benhamou Y
Liver Int; 2014 Feb; 34 Suppl 1():79-84. PubMed ID: 24373082
[TBL] [Abstract][Full Text] [Related]
19. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Asselah T; Marcellin P
Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
[TBL] [Abstract][Full Text] [Related]
20. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
Younossi Z; Henry L
Dig Liver Dis; 2014 Dec; 46 Suppl 5():S186-96. PubMed ID: 25458773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
